|
|
News Breaks | | | | December 10, 2012 | | 12:14 EDT |  | ASTX | Astex Pharmaceuticals announces SGI-110 Phase I clinical results
Astex Pharmaceuticals announced Phase I clinical results during a presentation at the American Society of Hematology of SGI-110, a novel second generation hypomethylation agent. Data from the completed SGI-110 dose escalation part of a randomized Phase 1/2 first-in-human clinical trial, in patients with relapsed/refractory intermediate or high-risk myelodysplastic syndromes or acute myelogenous leukemia demonstrated a differentiated pharmacokinetic profile resulting in an extended half-life and exposure to decitabine as delivered by subcutaneous SGI-110. "Excellent hypomethylation was achieved with higher doses in the daily regimen up to the Biologically Effective Dose," the company said. Treatment was well tolerated by most patients with the most common drug-related adverse events being expected myleosuppression, and Grade 1 injection site pain, Astex added. | |
|
News For ASTX From The Last 14 Days Check below for free stories on ASTX the last two weeks. |
|
|
| May 8, 2013 | | 06:11 EDT |  | ASTX | Astex Pharmaceuticals implied volatility at upper end of index mean range
 Subscribe for More Information | |
|
|
|
|
|
|
